Definitive Contract 75N93018C00030
Award Date
7/27/18
Potential Completion Date
7/31/20
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Adjuvance Technologies Inc. for the preclinical development of a semisynthetic saponin immunological adjuvant called Titerquil-1055 in the context of an influenza vaccine. The contract is a definitive, firm-fixed-price contract with a potential value of $1,471,319.00 and a completion date of December 15, 2020. The contract is...
This federal contract award, with ID 75N93023C00043, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of California San Diego (UCSD) for the "DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE". The $4,532,373.05 Firm Fixed Price contract has an ultimate completion date of September 29, 2028. UCSD, a non-profit, 1862 Land Grant College, is the prime contractor for this effort, which does...
This is a Firm Fixed Price definitive contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Adjuvance Technologies Inc. (doing business as Adjuvance) for the purpose of determining the impact of a semisynthetic saponin immunologic adjuvant called Titerquil-1055 on the immunogenicity and stability of influenza vaccines. The contract has a potential value of $223,002.00 and was completed on July 31,...
This federal contract award is for the development of UM-1098, a novel synthetic TH17 inducing adjuvant and delivery system. The prime contractor is the University of Montana, and major subcontractors include West Virginia University Research Corporation, Inimmune Corp, and the University of Chicago. The funding agency is the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...
This federal contract award, valued at $9,189,961.00, was granted to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a for-profit limited liability company based in Switzerland. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, for the Vaccine Adjuvant Discovery Program. This five-year definitive contract, running from September 2024...
The Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $599,980 firm fixed price contract to Tendel Therapies, Inc., a small business, for research and development services related to genetic adjuvants to promote durable anti-influenza stem antibodies in older adults. This contract was awarded under the NIH and Centers for Disease Control and Prevention's Small Business Innovation Research (SBIR) program,...
This firm-fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a for-profit biopharmaceutical company. The $599,629 contract funds the "Rational Development of a Combination Nanoparticle Adjuvant for Influenza", which involves research and development of novel adjuvants and other medical countermeasures. HDT Bio Corp has previously served as a prime contractor on other HHS...
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...